Tam K, Xie J, Au-Yeung R, Chiang A
PLoS Pathog. 2024; 20(9):e1012250.
PMID: 39325843
PMC: 11481030.
DOI: 10.1371/journal.ppat.1012250.
Sagou K, Sato Y, Okuno Y, Watanabe T, Inagaki T, Motooka Y
PLoS Pathog. 2024; 20(2):e1011954.
PMID: 38300891
PMC: 10833513.
DOI: 10.1371/journal.ppat.1011954.
Yoshizaki T, Kondo S, Dochi H, Kobayashi E, Mizokami H, Komura S
Microorganisms. 2024; 12(1).
PMID: 38276183
PMC: 10820804.
DOI: 10.3390/microorganisms12010014.
Papalexandri A, Gavriilaki E, Vardi A, Kotsiou N, Demosthenous C, Constantinou N
Int J Mol Sci. 2023; 24(22).
PMID: 38003218
PMC: 10671524.
DOI: 10.3390/ijms242216029.
Gorbea C, Elhakiem A, Cazalla D
Semin Cell Dev Biol. 2022; 146:20-30.
PMID: 36581481
PMC: 10101873.
DOI: 10.1016/j.semcdb.2022.12.008.
EBV-associated diseases: Current therapeutics and emerging technologies.
Chakravorty S, Afzali B, Kazemian M
Front Immunol. 2022; 13:1059133.
PMID: 36389670
PMC: 9647127.
DOI: 10.3389/fimmu.2022.1059133.
Are Viral Infections Key Inducers of Autoimmune Diseases? Focus on Epstein-Barr Virus.
Takei M, Kitamura N, Nagasawa Y, Tsuzuki H, Iwata M, Nagatsuka Y
Viruses. 2022; 14(9).
PMID: 36146707
PMC: 9506567.
DOI: 10.3390/v14091900.
Time-resolved transcriptomes reveal diverse B cell fate trajectories in the early response to Epstein-Barr virus infection.
SoRelle E, Dai J, Reinoso-Vizcaino N, Barry A, Chan C, Luftig M
Cell Rep. 2022; 40(9):111286.
PMID: 36044865
PMC: 9879279.
DOI: 10.1016/j.celrep.2022.111286.
Integrative Transcriptomics and Proteomics Analysis Provide a Deep Insight Into Bovine Viral Diarrhea Virus-Host Interactions During BVDV Infection.
Ma Y, Wang L, Jiang X, Yao X, Huang X, Zhou K
Front Immunol. 2022; 13:862828.
PMID: 35371109
PMC: 8966686.
DOI: 10.3389/fimmu.2022.862828.
[The diagnostic value of whole blood Epstein-Barr virus DNA load in lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].
Niu Y, Dong Y, Yin Y, Xu W, Liang Z, Wang Q
Zhonghua Xue Ye Xue Za Zhi. 2022; 42(11):904-910.
PMID: 35045651
PMC: 8763583.
DOI: 10.3760/cma.j.issn.0253-2727.2021.11.004.
Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
Cui X, Snapper C
Front Immunol. 2021; 12:734471.
PMID: 34691042
PMC: 8532523.
DOI: 10.3389/fimmu.2021.734471.
Calcium-dependent signalling in B-cell lymphomas.
Berditchevski F, Fennell E, Murray P
Oncogene. 2021; 40(45):6321-6328.
PMID: 34625709
PMC: 8585665.
DOI: 10.1038/s41388-021-02025-8.
Possible role of HPV/EBV coinfection in anoikis resistance and development in prostate cancer.
Nahand J, Khanaliha K, Mirzaei H, Moghoofei M, Baghi H, Esghaei M
BMC Cancer. 2021; 21(1):926.
PMID: 34399719
PMC: 8369687.
DOI: 10.1186/s12885-021-08658-y.
A Systematic Review of the Potential Implication of Infectious Agents in Myasthenia Gravis.
Leopardi V, Chang Y, Pham A, Luo J, Garden O
Front Neurol. 2021; 12:618021.
PMID: 34194378
PMC: 8236805.
DOI: 10.3389/fneur.2021.618021.
EBV miRNAs are potent effectors of tumor cell transcriptome remodeling in promoting immune escape.
Ungerleider N, Bullard W, Kara M, Wang X, Roberts C, Renne R
PLoS Pathog. 2021; 17(5):e1009217.
PMID: 33956915
PMC: 8130916.
DOI: 10.1371/journal.ppat.1009217.
The potential of proliferative and apoptotic parameters in clinical flow cytometry of myeloid malignancies.
Mestrum S, Hopman A, Ramaekers F, Leers M
Blood Adv. 2021; 5(7):2040-2052.
PMID: 33847740
PMC: 8045496.
DOI: 10.1182/bloodadvances.2020004094.
BCL-XL inhibition by BH3-mimetic drugs induces apoptosis in models of Epstein-Barr virus-associated T/NK-cell lymphoma.
Sejic N, George L, Tierney R, Chang C, Kondrashova O, MacKinnon R
Blood Adv. 2020; 4(19):4775-4787.
PMID: 33017468
PMC: 7556124.
DOI: 10.1182/bloodadvances.2020002446.
Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas.
Pei Y, Wong J, Robertson E
Cancers (Basel). 2020; 12(9).
PMID: 32916819
PMC: 7564798.
DOI: 10.3390/cancers12092565.
Epstein-Barr Virus Facilitates Expression of KLF14 by Regulating the Cooperative Binding of the E2F-Rb-HDAC Complex in Latent Infection.
Pei Y, Wong J, Jha H, Tian T, Wei Z, Robertson E
J Virol. 2020; 94(22).
PMID: 32847849
PMC: 7592212.
DOI: 10.1128/JVI.01209-20.
The BCL-2 family protein inhibitor ABT-737 as an additional tool for the treatment of EBV-associated post-transplant lymphoproliferative disorders.
Robert A, Pujals A, Favre L, Debernardi J, Wiels J
Mol Oncol. 2020; 14(10):2520-2532.
PMID: 32623836
PMC: 7530790.
DOI: 10.1002/1878-0261.12759.